Old Web
English
Sign In
Acemap
>
authorDetail
>
David Magrez
David Magrez
Ursodeoxycholic acid
Medicine
Virology
Peroxisome proliferator
Elafibranor
3
Papers
71
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
2021
Journal of Hepatology
Jörn M. Schattenberg
Albert Parés
Kris V. Kowdley
Michael A. Heneghan
Stephen H. Caldwell
Daniel S. Pratt
Alan Bonder
Gideon M. Hirschfield
Cynthia Levy
John M. Vierling
David Jones
Anne Tailleux
Bart Staels
S. Megnien
Rémy Hanf
David Magrez
Pascal Birman
Velimir A. Luketic
Show All
Source
Cite
Save
Citations (9)
LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment
2019
Journal of Hepatology
Pd Dr. Schattenberg Jörn
Albert Parés
Kris V. Kowdley
Michael A. Heneghan
Stephen H. Caldwell
Daniel S. Pratt
Alan Bonder
Gideon M. Hirschfield
Mb BChir
Cynthia Levy
John M. Vierling
David Jones
S. Megnien
Rémy Hanf
David Magrez
Pascal Birman
Velimir A. Luketic
Show All
Source
Cite
Save
Citations (9)
Issues in performing a network meta-analysis
2013
Statistical Methods in Medical Research
Stephen Senn
François Gavini
David Magrez
André Scheen
Show All
Source
Cite
Save
Citations (53)
1